

Particulars	CONSOLIDATED				
	Quarter Ended			Year Ended	Year Ended
	March-13	December-12	March-12	March-13	March-12
PART- I	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1 (a) Net Sales / Income from Operations					
Domestic	23,624	25,470	20,373	100,877	87,718
Exports	14,212	11,735	13,857	51,723	59,071
Total	37,836	37,205	34,230	152,600	146,789
Less : Excise Duty	178	325	151	875	554
Net Sales / Income from Operations	37,658	36,880	34,079	151,725	146,235
(b) Other Operating Income	150	44	155	309	306
Total Income from Operations	37,808	36,924	34,234	152,034	146,541
2 Expenses					
(a) Decrease/(Increase) in stock in trade and work in progress	2,550	(2,223)	(3,435)	2,134	(6,444)
(b) Consumption of Raw Materials & Packing Materials	10,810	12,420	12,684	47,030	52,824
(c) Purchase of traded goods	3,348	4,866	6,055	18,906	24,412
(d) Employees' Cost	5,077	4,952	4,311	19,379	16,846
(e) Research and Development Expense	2,200	2,172	2,214	7,363	5,858
(f) Excise Duty	171	(302)	311	100	509
(g) Other Expenditure	7,094	8,103	8,011	31,926	30,593
Total Expenses	31,250	29,988	30,149	126,838	124,597
3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	6,558	6,936	4,084	25,196	21,943
4 Other Income	7	346	40	393	142
5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	6,565	7,282	4,125	25,589	22,086
6 Depreciation	864	885	892	3,497	3,365
7 Interest (Net)	183	388	538	1,457	2,621
8 Net Profit / (Loss) from Ordinary Activities before Tax	5,518	6,009	2,694	20,635	16,099
9 Tax Expense					
Less : Provision for Current Tax	1,017	1,211	526	4,014	3,123
Less/(Add) : Provision for Deferred Tax Liability /(Assets)	136	(29)	137	96	(38)
10 Net Profit / (Loss) from Ordinary Activities after Tax	4,365	4,827	2,031	16,525	13,014
11 Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770	3,770
12 Reserves excluding Revaluation Reserve	-	-	-	46,524	35,730
13 Debenture Redemption Reserve	-	-	-	-	3,125
14 Basic & Diluted EPS (Not Annualised)	2.32	2.56	1.08	8.77	6.90
15 Debt Equity Ratio				0.33	0.94
16 Debt Service Coverage Ratio				-	3.06
17 Interest Service Coverage Ratio				-	12.40
PART- II					
A Particulars of Shareholding					
1 Public Shareholding					
- Number of Shares	48777294	48777294	48763089	48777294	48763089
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2 Promoters and Promoter Group Shareholding					
- Fully Non - Encumbered					
- Number of Shares	139738620	139738620	139752825	139738620	139752825
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS	Quarter ended on 31st March, 2013				
Pending at the beginning of the quarter					NIL
Received during the quarter					2
Disposed of during the quarter					2
Remaining unresolved at the end of the quarter					NTI

Notes :

- 1 The above results, duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The results include duly audited financial statements of Company's Subsidiary Alembic Global Holding SA (AGH), but consolidation of newly set-up step down subsidiaries of AGH have not been audited as the same are not yet operational. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Board has recommended dividend on Equity Shares at Rs. 2.50 per share i.e. 125% for the year ended on 31.03.2013 (PY Rs. 1.40 per share)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 2nd May, 2013

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com

	Particulars	STANDALONE				
		Quarter Ended			Year Ended	Year Ended
		March-13	December-12	March-12	March-13	March-12
		(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	(a) Net Sales / Income from Operations					
	Domestic	23,624	25,470	20,373	100,877	87,718
	Exports	14,177	11,735	11,454	48,952	49,961
	Total	37,801	37,205	31,827	149,829	137,679
	Less : Excise Duty	178	325	151	875	554
	Net Sales / Income from Operations	37,623	36,880	31,676	148,954	137,125
	(b) Other Operating Income	150	44	155	309	306
	Total Income from Operations	37,773	36,924	31,830	149,262	137,430
2	Expenses					
	(a) Decrease/(increase) in stock in trade and work in progress	2,550	(2,223)	(3,435)	2,134	(6,444)
	(b) Consumption of Raw Materials & Packing Materials	10,810	12,420	12,684	47,030	52,824
	(c) Purchase of traded goods	3,348	4,866	4,110	16,559	16,779
	(d) Employees' Cost	5,077	4,952	4,311	19,379	16,846
	(e) Research and Development Expense	2,200	2,172	2,214	7,363	5,858
	(f) Excise Duty	171	(302)	311	100	509
	(g) Other Expenditure	7,446	8,019	7,712	32,322	30,200
	Total Expenses	31,602	29,904	27,906	124,886	116,571
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	6,171	7,020	3,924	24,376	20,859
4	Other Income	7	346	40	393	142
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	6,178	7,366	3,964	24,769	21,001
6	Depreciation	864	885	892	3,496	3,365
7	Interest (Net)	183	388	538	1,457	2,621
8	Net Profit / (Loss) from Ordinary Activities before Tax	5,131	6,093	2,534	19,816	15,015
9	Tax Expense					
	Less : Provision for Current Tax	1,024	1,222	508	3,975	3,000
	Less /Add : Provision for Deferred Tax Liability/(Assets)	136	(29)	137	96	(38)
10	Net Profit / (Loss) from Ordinary Activities after Tax	3,971	4,900	1,890	15,745	12,054
11	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve	-	-	-	42,206	32,316
13	Debenture Redemption Reserve	-	-	-	-	3,125
14	Basic & Diluted EPS (Not Annualised)	2.11	2.60	1.00	8.35	6.39
15	Debt Equity Ratio				0.36	1.02
16	Debt Service Coverage Ratio				-	2.91
17	Interest Service Coverage Ratio				-	11.76
	PART- II					
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48777294	48777294	48763089	48777294	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139738620	139738620	139752825	139738620	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter ended on 31st March, 2013				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	2				
	Disposed of during the quarter	2				
	Remaining unresolved at the end of the quarter	NIL				

Notes :

- 1 The above results, duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The results include duly audited financial statements of Company's Subsidiary Alembic Global Holding SA (AGH), but consolidation of newly set-up step down subsidiaries of AGH have not been audited as the same are not yet operational. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Board has recommended dividend on Equity Shares at Rs. 2.50 per share i.e. 125% for the year ended on 31.03.2013 (PY Rs. 1.40 per share)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 2nd May, 2013

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com

Alembic Pharmaceuticals Limited

Consolidated Statement of Assets and Liabilities

Rs. In Lacs

Particulars	As at 31st March, 2013 (Audited)	As at 31st March, 2012 (Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	3,770	3,770
(b) Reserves and surplus	46,524	35,730
Sub-total - Shareholders' funds	50,294	39,500
2 Non-current liabilities		
(a) Long-term borrowings	7,053	9,486
(b) Deferred tax liabilities (net)	1,390	953
(c) Other long-term liabilities	1,276	1,229
(d) Long-term provisions	606	539
Sub-total - Non-current liabilities	10,325	12,207
3 Current liabilities		
(a) Short-term borrowings	7,011	13,843
(b) Trade payables	23,996	20,915
(c) Other current liabilities	6,925	15,160
(d) Short-term provisions	6,230	3,566
Sub-total - Current liabilities	44,163	53,485
TOTAL - EQUITY AND LIABILITIES	104,782	105,191
B ASSETS		
1 Non-current assets		
(a) Fixed assets	37,648	32,606
(b) Non-current investments	330	330
(c) Long-term loans and advances	3,588	3,499
Sub-total - Non-current assets	41,566	36,435
2 Current assets		
(a) Inventories	26,683	25,874
(b) Trade receivables	23,287	19,933
(c) Cash and Bank Balance	1,611	4,709
(d) Short-term loans and advances	11,635	18,240
Sub-total - Current assets	63,216	68,756
TOTAL - ASSETS	104,782	105,191

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 2nd May, 2013

Chirayu Amin
Chairman and Managing Director